---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000035"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-08-03T10:46:50+00:00"
generated_at: "2026-08-03T10:50:09.762292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Supernus Q2 revenue up 32% to $219.1M; raises FY guidance; announces merger with Indivior

## Summary
- Total revenues $219.1M, +32% YoY; growth products revenue $175.7M, +52% YoY.
- Qelbree net sales $89.2M (+15% YoY); GOCOVRI $37.6M (+2%); ONAPGO $13.5M; ZURZUVAE collab rev $35.4M.
- Company raises full-year 2026 financial guidance.
- Agreed to merge with Indivior in all-stock merger of equals, creating diversified CNS company.
- ONAPGO second supplier regulatory submission on track for Q3 2026, potential FDA approval by mid-2027.

## SEC filing metadata
- accession: 0001356576-26-000035
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-08-03T10:46:50+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/0001356576-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/supn-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000035
- JSON: https://secwatch.observer/filing/0001356576-26-000035.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.